The Medicines Company (NASDAQ:MDCO) has been under a strong bear grip, hence the stock is down -7.82% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.99% in the past 1 week. The stock has risen by 2.29% in the past week indicating that the buyers are active at lower levels, but the stock is down -6.33% in the past 4 weeks.
The company shares have rallied 5.28% from its 1 Year high price. On Sep 17, 2015, the shares registered one year high at $43.79 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $35.82 and the 200 Day Moving Average price is recorded at $34.15.
The stock has recorded a 20-day Moving Average of 0.11% and the 50-Day Moving Average is 2.13%.
The Medicines Company (NASDAQ:MDCO): stock turned positive on Friday. Though the stock opened at $34.57, the bulls momentum made the stock top out at $35.04 level for the day. The stock recorded a low of $34.05 and closed the trading day at $34.9, in the green by 1.48%. The total traded volume for the day was 1,700,592. The stock had closed at $34.39 in the previous days trading.
In an insider trading activity, Cox Christopher T, officer (EVP & Chief Corp. Dev. Officer) of Medicines Co /De, executed a transaction worth $1,729,956 on June 8, 2016. A total of 45,985 shares were purchased at an average price of $37.62. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.